Navigation Links
Src Inhibitors in Breast Cancer Therapy

Estrogen, which binds estrogen receptor alpha (ER-alpha), is a risk factor for breast cancer development. However, one-third of new breast cancers lack detectable ER-alpha .

These ER-alphanegative cancers are more aggressive and have a worse prognosis than do ER-alphapositive breast cancers, and have been thought to be estrogen independent.

In a study appearing online on July 12 in advance of publication in the August print issue of the Journal of Clinical Investigation, Joyce Slingerland and colleagues from the University of Miami shed further light on the mechanisms regulating ER-alpha expression levels during breast cancer.

In their study of 250 primary breast cancers, the authors found that ER mRNA levels overlap considerably between ER-alphapositive and ER-alphanegative breast cancers.

This lack of correlation between ER-alpha mRNA and protein levels pointed to the existence of important post-transcriptional control of ER-alpha expression.

They found that ER-alphanegative primary breast cancers and cell lines showed increased levels and/or activity of the protein Src, which cooperates with estrogen to activate ER-alpha breakdown via proteolysis.

In line with this finding, Src inhibition was shown to impair estrogen-stimulated ER-alpha proteolysis. The data raise the possibility that for at least a subset of ER-alphanegative breast cancers, Src may stimulate estrogen-dependent ER-alpha degradation, resulting in a lack of ER-alpha detection, and more aggressive tumor growth.

The authors conclude that their study provides a rationale for the use of Src inhibitors in breast cancer therapy.

AUTHOR CONTACT: Joyce M. Slingerland University of Miami Miller School of Medicine, Miami, Florida, USA. Phone : (305) 243-7265; Fax: (305) 243-4787; E-mail: jslingerland@med.miami.edu


'"/>




Page: 1

Related medicine news :

1. Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence
2. LipB Protein Inhibitors Help To Fight Against TB
3. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
4. ACE Inhibitors For Vascular Disease Patients
5. Green Tea and COX-2 Inhibitors Combine to Slow Growth of Prostate Cancer
6. Consensus on "Combination Therapy" for Breast Cancer
7. Breast cancer treatment to be determined by gene test
8. Breast Feeding prevents obesity later on in life
9. Breast milk is essential
10. Breast Cancer Surgery Causes Psychological problems
11. Breast cancer evidence
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
Breaking Medicine Technology: